Search

Search Results

• 

  Anticoagulation in obese patients: challenges and strategies

  Alice Lipari, Esmeralda Capristo, Antonietta Ferretti, Erica De Candia

  18-09-2025

  https://doi.org/10.4081/btvb.2025.174

  2029

  PDF: 530

  HTML: 303

  XML: 186
• 

  The key to fibrinolysis and thrombolysis

  Roger Lijnen, Désiré Collen

  09-09-2025

  https://doi.org/10.4081/btvb.2025.368

  1692

  PDF: 523

  HTML: 261
• 

  Diagnostic and management practices for inherited fibrinogen disorders: a nationwide survey of Italian Hemophilia Treatment Centers

  Renato Marino, Silvia Linari, Marzia Leotta, Antonio Coppola, Chiara Biasoli, Maria Elisa Mancuso, Flora Peyvandi, Cristina Santoro, Ezio Zanon, Rita Carlotta Santoro

  02-12-2025

  https://doi.org/10.4081/btvb.2025.372

  920

  PDF: 119

  HTML: 122

  Supplementary: 79

  Appendix: 79
• 

  Bioequivalence of von Willebrand factor-containing concentrates: implications for the choice in patients with von Willebrand disease. A position paper from the Italian Association of Hemophilia Centers

  Ezio Zanon, Giancarlo Castaman, Augusto Bramante Federici, Maria Elisa Mancuso, Gianfranco Pasut, Alberto Tosetto, Angiola Rocino, Rita Carlotta Santoro

  26-01-2026

  https://doi.org/10.4081/btvb.2026.415

  1290

  PDF: 344

  HTML: 163
• 

  The landscape of rare coagulation factor deficiency management in Italy: a national hemophilia center survey

  Silvia Linari, Renato Marino, Marzia Leotta, Antonio Coppola, Patrizia Di Gregorio, Augusto Bramante Federici, Flora Peyvandi, Cristina Santoro, Ezio Zanon, Rita Carlotta Santoro

  05-11-2025

  https://doi.org/10.4081/btvb.2025.369

  1350

  PDF: 218

  HTML: 133

  Appendix: 119

• CO091 | DOWNREGULATION OF MARKERS OF PLATELET ACTIVATION, PLATELET TURNOVER, AND PLATELET DESIALYLATION IN GOOD RESPONDERS TO FIRST-LINE TREATMENT(S) FOR IMMUNE THROMBOCYTOPENIA B. Clerici^1|2, C. Ghali², M. Scavone², A. Fioretti², E.G. Bossi², S. Birocchi¹, E. Tarasconi^1|2, G. D'Avanzo¹, M. Carpenedo³, S. Caberlon², G.M. Podda^1|2 | ¹.S.C. Medicina Generale SP, Ospedale San Paolo, ASST Santi Paolo e Carlo, Milano, Italy; ²Dipartimento di Scienze della Salute (DISS), Università degli Studi di Milano, Italy; ³S.S. Ematologia Non Oncologica, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy. B. Clerici and C. Ghali contributed as co-first authors

  Bianca Clerici

  26-10-2026

  https://doi.org/10.4081/btvb.2026.793

  8

  PDF: 2
• 

  Still unmet problems with low molecular weight heparin prophylaxis of venous thromboembolism. An Italian survey

  Stefania Cavazza, Gualtiero Palareti*

  03-10-2025

  https://doi.org/10.4081/btvb.2025.177

  1445

  PDF: 305

  HTML: 202

  Supplementary: 102
• 

  PO34 | INVESTIGATORS’ DECISIONS ON ANTICOAGULATION AFTER EXTENDED API-CAT TREATMENT FOR CANCER VENOUS THROMBOEMBOLISM I. Mahé^1|4, F. Happe², M. Monreal^5|7, H. Robert-Ebadi⁸, P. Debourdeau⁹, J. R. Fabreguettes¹⁰, S. Accassat¹¹, P. Mismetti^4|11|12, P. Girard¹³, S. Laporte^4|12|14, C. Chapelle¹⁴ | ¹Paris Cité University; ²Assistance Publique - Hôpitaux de Paris, Louis Mourier Hospital, Department of Internal Medicine; ³Inserm UMR-S970, Paris Cardiovascular Research Center, Team « Endotheliopathy and Hemostasis Disorders », Paris, France; ⁴F-CRIN INNOVTE Network, France; ⁵Department of Internal Medicine, Institut de Recerca Germans Trias i Pujol, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; ⁶Department of Medicine, Universitat Autonoma de Barcelona, Barcelona; ⁷Universidad Catolica San Antonio de Murcia, Murcia, Spain; ⁸Division of Angiology and Hemostasis, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland; ⁹Arles Hospital, Oncology unit, Arles, France; ¹⁰Assistance Publique - Hôpitaux de Paris, AGEPS, France; ¹¹Service de Médecine Vasculaire et Therapeutique, CHU de Saint-Etienne, Saint-Etienne, France; ¹²Université Jean Monnet, Mines Saint-Étienne, INSERM Unité 1059, Santé Ingénierie Biologie Saint-Étienne SAINBIOSE, Saint-Étienne, France; ¹³Département de Pneumologie, Institut Mutualiste Montsouris, Paris; ¹⁴Service de Pharmacologie Clinique, CHU de Saint-Etienne, Saint-Etienne, France

  ICTHIC 2026

  16-04-2026

  https://doi.org/10.4081/btvb.2026.528

  423

  PDF: 90

• CO092 | FOSTAMATINIB IN CHRONIC IMMUNE THROMBOCYTOPENIA: A REAL-WORLD MONOCENTRIC EXPERIENCE M. Biglietto, S. Sorella, S. Ligia, S. Santostefano, R. Celia, R. Mormile, E. Baldacci, A. Chistolini, C. Santoro | Sapienza University of Roma, Italy

  Mario Biglietto

  26-10-2026

  https://doi.org/10.4081/btvb.2026.794

  9

  PDF: 2

• PO44 | Emicizumab in acquired haemophilia A M. Leotta, A. Strangio, A. Ierardi, S. Prejanò, R C. Santoro | Hemostasis and Thrombosis Unit, Department Hemato-Oncology, Azienda Ospedaliero-Universitaria Renato; Dulbecco, Catanzaro, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.307

  619

  PDF: 20

• PO091 | RESPONSE AND CARDIOVASCULAR SAFETY OF FOSTAMATINIB IN CHRONIC IMMUNE THROMBOCYTOPENIA: A REAL WORLD ANALYSIS C. Giubbilei, G. Giustini, A. Baffioni, V. Carrai | SOD Ematologia, Azienda Universitaria Ospedaliera Careggi, Firenze, Italy

  Cristina Giubbilei

  26-10-2026

  https://doi.org/10.4081/btvb.2026.907

  7

  PDF: 2

• PO50 | Treatment with BTK inhibitors in patients affected by chronic lymphocytic leukemia: safety and hemostasis L. Gurgoglione, C.A. Piro, I. Scortechini, I. Battilà, M.C. Merlo, A. R. Scortechini, S. Rupoli, A. Poloni | Hematology Unit, AOU delle Marche-Università Politecnica delle Marche, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.319

  516

  PDF: 14

• PO156 | DIRECT ORAL ANTICOAGULANTS FOR THE TREATMENT OF VTE IN PATIENTS WITH CANCER: A SURVEY AMONG CAMPANIAN INTERNAL MEDICINE WARDS E. Marrone¹, C. Arturo², F. Cannavacciulo³, D. D’Ambrosio⁴, F. Gallucci¹, M. Amitrano³, C. Di Gennaro², P. Morella¹, A. Maffettone⁵ | ¹UOC Medicina 3, AORN A Cardarelli, Napoli, Italy; ²UOC Medicina Generale, PO A. Rizzoli, Ischia, Italy; ³UOC Medicina Interna, AO Moscati, Avellino, Italy; ⁴UOC Medicina Generale, PO Piedimonte Matese ASL Caserta, Italy; ⁵UOC Medicina interna, PO San Luca, Vallo Della Lucania ASL Salerno, Italy

  Emiliana Marrone

  26-10-2026

  https://doi.org/10.4081/btvb.2026.972

  5

  PDF: 2

• PO155 | MANAGEMENT OF ANTICOAGULANT THERAPY IN IMMUNOTHROMBOSIS SECONDARY TO TOXOPLASMA INFECTION A. Grembiale¹, A. Sabena¹, G. Dettori¹, C. Grendene¹, S. Grazioli¹, S. Venturini² | ¹SOC Medicina Interna 2 - Azienda Sanitaria Friuli Occidentale - Pordenone, Italy; ²SSD Malattie Infettive - Azienda Sanitaria Friuli Occidentale - Pordenone, Italy

  Alessandro Grembiale

  26-10-2026

  https://doi.org/10.4081/btvb.2026.971

  8

  PDF: 2

• CO094 | ASSESSMENT OF THE MINIMAL EFFECTIVE DOSE OF AVATROMBOPAG IN IMMUNE THROMBOCYTOPENIA: A SINGLE-CENTER REAL-WORLD STUDY A. Baffioni¹, C. Giubbilei¹, G. Giustini¹, A.M. Vannucchi², V. Carrai³ | ¹SOD Ematologia, Università degli studi di Firenze, Italy; ²Center for Innovation and Research in Myeloproliferative Neoplasms, SOD Ematologia, Azienda Ospedaliera Universitaria Careggi, Università degli studi di Firenze, Italy; ³SOD Ematologia, Dipartimento di Oncologia, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy

  Agnese Baffioni

  26-10-2026

  https://doi.org/10.4081/btvb.2026.796

  5

  PDF: 2

• PO089 | A RISK-ADAPTED, MULTIDISCIPLINARY CONSENSUS FOR ADULT ITP MANAGEMENT: BRIDGING GUIDELINES AND REAL-WORLD PRACTICE A. Votto¹, E. Pacini², G. Giustini³, I. Rina¹, S. Galimberti¹ | ¹Department of Clinical and Experimental Medicine, University of Pisa, Italy; ²Hematology Unit, University of Siena, Azienda Ospedaliera Universitaria Senese, Italy; ³Hematology Unit, AOU Careggi, Firenze, Italy

  Amedeo Votto

  26-10-2026

  https://doi.org/10.4081/btvb.2026.905

  6

  PDF: 2

• PO005 | EXTENDED ANTICOAGULATION WITH DOACS IN PATIENTS AFFECTED BY HEMATOLOGIC MALIGNANCIES AND VENOUS THROMBOEMBOLISM: DOES LOW DOSE FIT ALL? M. Biglietto, S. Sorella, L.V. Cappelli, B. Mandelli, D. Kasmi, E. Baldacci, A. Chistolini | Sapienza University of Roma, Italy

  Mario Biglietto

  26-10-2026

  https://doi.org/10.4081/btvb.2026.821

  2

  PDF: 2

• PO46 | Intravitreal treatment with faricimab in patients with age-related macular degeneration M. Alfonsetti¹, R. Liani¹, P.G.M. Simeone¹, M. Frezza¹, A. Ricci³, S. Lattanzio¹, R. D’Aloisio², L. Toto², F. Santilli¹ | ¹Department of Medicine and Aging, Center for Advanced Studies and Technology “CAST”; ²Ophthalmology Clinic, Department of Medicine and Aging; ³Department of Pharmacy, University “G. d’Annunzio” of Chieti Pescara, Chieti, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.315

  476

  PDF: 15

• PO59 | Efficacy and safety of different anticoagulant treatment regimens for isolated internal jugular vein thrombosis: a case series A. Pannunzio¹, E. Valeriani¹, I.M. Palumbo¹, S. Marucci², D. Menichelli¹, D. Pastori², P. Pignatelli² | ¹Department of General Surgery and Surgical Specialty, Sapienza University of Roma; ²Department of Clinical, Internal Medicine, Anaesthesiological and Cardiovascular Sciences, Sapienza University of Roma, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.328

  691

  PDF: 31

• CO012 | LONG-TERM RISK OF RECURRENT VENOUS THROMBOEMBOLISM IN ADULT PATIENTS WITH ACTIVE CANCER AND FIRST CATHETER-RELATED UPPER EXTREMITY DEEP VEIN THROMBOSIS AFTER DISCONTINUATION OF ANTICOAGULANT TREATMENTS AND LINE REMOVAL: A RETROSPECTIVE MULTI-CENTER COHORT STUDY – CANCER-CRT STUDY L. Girardi^1|2, W. Ageno³, L. Bertù¹, C. Lodigiani⁴, L.A. Ciuffini⁴, M.C. Vedovati⁵, C. Becattini⁵, A. Sammarco⁶, G. Camporese⁶, G. Cuni^1|7, C. Ambaglio⁷, M.P. Donadini¹ | ¹Research Center on Thromboembolic Diseases and Antithrombotic Treatment, Department of Medicine and Surgery, University of Insubria, Varese, Italy; ²Department of Medicine, The Ottawa Hospital Research Institute, University of Ottawa, Ontario, Canada; ³Department of Medicine, University of Padua, Padova, Italy; ⁴Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy; ⁵Internal and Cardiovascular Medicine-Stroke Unit, University of Perugia, Perugia, Italy; ⁶Clinica Medica 1, Department of Medicine, DIMED, Padova University Hospital, Padova, Italy; ⁷Immunohematology and Transfusion Medicine, Department of Transfusion Medicine and Hematology, ASST Papa Giovanni XXIII, Bergamo, Italy

  Laura Girardi

  26-10-2026

  https://doi.org/10.4081/btvb.2026.714

  6

  PDF: 2

• PO43 | Extended treatment with reduced dose of direct oral anticoagulants in patients with venous thromboembolism: a retrospective study A. Pannunzio¹, E. Valeriani¹, I.M. Palumbo¹, D. Menichelli¹, T. Brogi², S. Marucci², D. Pastori², P. Pignatelli² | ¹Department of General Surgery and Surgical Specialty, Sapienza University of Roma; ²Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Roma, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.306

  649

  PDF: 27
• 

  Venous thromboembolism treatment in patients with cancer: reflections on an evolving landscape

  Agnes Y.Y. Lee

  29-02-2024

  https://doi.org/10.4081/btvb.2024.111

  2140

  PDF: 1368
• 

  Successful treatment of aortic arch mural thrombosis with low-dose, ultra-slow-flow thrombolysis: a case report and literature review

  Rosina Albisinni, Tommaso Marrazzo, Arta Karruli, Sabrina Manduca, Giuseppe Nobile, Nicola Galdieri, Marisa De Feo

  24-10-2022

  https://doi.org/10.4081/btvb.2022.44

  1476

  PDF: 411

• CO035 | THE ROLE OF INFLAMMATORY BIOMARKERS IN IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA F. Schieppati^1|2, S. Bolognini^1|2, C. Ticozzi¹, O.C. Cretu¹, P. Gomez-Rosas^1|3, M. D’Adda⁴, V. Cancelli⁴, C. Ambaglio¹, E. Galimberti¹, L. Barcella¹, A. Falanga^1|2, M. Marchetti^1|2 | ¹Immunohematology and Transfusion Medicine, Department of Transfusion Medicine and Hematology, ERN-EuroBloodNet - European Reference Network in Rare Hematological Diseases, ASST Papa Giovanni XXIII, Bergamo, Italy; ²School of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy; ³Maastricht University Medical Center, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands; ⁴Hematology, Hospital Spedali Civili di Brescia, Brescia, Italy

  Francesca Schieppati

  26-10-2026

  https://doi.org/10.4081/btvb.2026.737

  7

  PDF: 2

• PO118 | VARIATION OF EGFR IN PATIENT IN DOACS THERAPY S. Vivolo, C. Gagliardi, A. Ciampa | U.O.S.D. Centro Emostasi Aorn S. G. Moscati Avellino, Italy

  Sabrina Vivolo

  26-10-2026

  https://doi.org/10.4081/btvb.2026.934

  2

  PDF: 2

• CO-50 | LEFT ATRIAL APPENDAGE OCCLUSION IN PATIENTS WITH ATRIAL FIBRILLATION AND BLEEDING DISORDERS: A SINGLE-CENTER EXPERIENCE B.M. Roccon¹, M.I. Tassoni¹, G. Quintavalle¹, G. Benatti², F. Gurgoglione², R. Rossi³, C. Cattabiani³, L. Vignali², A. Tagliaferri¹, A. Coppola¹ | ¹SSD Centro Hub Emofilia e Malattie Emorragiche Congenite, Azienda Ospedaliero-Universitaria di Parma, Italy; ²SSD Cardiologia Interventistica, Azienda Ospedaliero-Universitaria di Parma, Italy; ³Laboratorio di Coagulazione, UOC Patologia Clinica, Azienda Ospedaliero-Universitaria di Parma, Italy

  Antonio Coppola

  14-10-2026

  https://doi.org/10.4081/btvb.2026.660

  33

  PDF: 16

• PO028 | SUSTAINED RESPONSE OFF TREATMENT IN ITP PATIENTS TREATED WITH TPO-RA: A SINGLE-CENTER EXPERIENCE A. Baffioni¹, C. Giubbilei¹, G. Giustini¹, A.M. Vannucchi², V. Carrai³ | ¹SOD Ematologia, Università degli studi di Firenze, Italy; ²Center for Innovation and Research in Myeloproliferative Neoplasms, SOD Ematologia, Azienda Ospedaliera Universitaria Careggi, Università degli studi di Firenze, Italy; ³SOD Ematologia, Dipartimento di Oncologia, Azienda Ospedaliera Universitaria Careggi. Firenze, Italy

  Agnese Baffioni

  26-10-2026

  https://doi.org/10.4081/btvb.2026.844

  5

  PDF: 2

• PO28 | Long term effectiveness and safety of venous thromboembolism with fondaparinux: data from the start registry I.M. Palumbo¹, E. Valeriani^1,2, A. Pannunzio¹, S. Marucci³, D. Menichelli¹, D. Pastori^3,4, P. Pignatelli³ | ¹Department of General Surgery and Surgical Specialty, Sapienza University of Roma; ²Department of Infectious Disease, Azienda Ospedaliero-Universitaria Policlinico Umberto I, Roma; ³Department of Clinical Internal, Anaesthesiologic and Cardiovascular Sciences, Sapienza University of Roma, Roma; ⁴IRCCS NeuRomad, Pozzilli, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.289

  634

  PDF: 12
• 

  Pathways for lower extremity superficial vein thrombosis management in an academic medical center

  Gisoo Imani, Aaron Wilson, Sara Vazquez, Daniel M. Witt

  24-03-2025

  https://doi.org/10.4081/btvb.2025.155

  872

  PDF: 265
• 

  Risk of recurrent venous thromboembolism in cancer patients after discontinuation of anticoagulant therapy

  Gary E. Raskob

  16-05-2024

  https://doi.org/10.4081/btvb.2024.124

  1677

  PDF: 1243

• CO074 | WHOLE-BLOOD COAGULATION AND PLATELET DYNAMICS IDENTIFY DIFFERENTIAL PROTHROMBOTIC STATES IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH JAK OR TNFⱭ INHIBITORS L. Spiezia, A. Giollo, L. Di Luozzo, M. Salvato, K. Khalid, R. D’Andrea, A. Benetti, C. Samà, R. Ramonda, P. Simioni | Dipartimento di Medicina, Azienda Osp. Università di Padova, Italy

  Luca Spiezia

  26-10-2026

  https://doi.org/10.4081/btvb.2026.776

  7

  PDF: 2

• PO02 | Pregnancy and delivery in women with hemophilia and carriers are still challenging: a ten years analysis from The Italian Association of Hemophilia Centers (AICE) M. Napolitano¹, M. Mattana², C. Cammarata¹, M. Leotta³, S. Linari⁴, M.E. Mancuso⁵, G. F. Rivolta⁶, C. Santoro⁷, L. Valdrè⁸, R.C. Santoro³, S. Siragusa¹ | ¹Department of Health Promotion, Mother and Child Care, Internal Medicine and Med, Palermo; University of Palermo, Italy; ²Department of Precision Medicine in Medical, Surgical and Critical Care “Me. Pre. Cc”, University of Palermo; ³Hemostasis and Thrombosis Unit, Azienda Ospedaliera Universitaria Dulbecco, Catanzaro; ⁴Center for Bleeding Disorders, Careggi University Hospital, Firenze; ⁵Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milan; ⁶Regional Reference Center for the Treatment of Congenital Hemorrhagic Diseases, Parma University Hospital, Parma; ⁷Hematology, University Hospital Policlinico Umberto I, Roma; ⁸Inherited Bleeding Disorders Unit, IRCCS AOUBO, Bologna, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.312

  689

  PDF: 19
• 

  PO53 | PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF REGN7508^CAT FOR PRIMARY PROPHYLAXIS OF CANCER-ASSOCIATED THROMBOSIS FOR PARTICIPANTS WITH SOLID TUMORS UNDERGOING CANCER TREATMENT (ROXI-CAT-I) J. Zwicker¹, M. P. O’Brien², M. Carrier³, J. Connors⁴, A. Falanga⁵, A. Manzano⁶, R. Mcbane⁷, Y.Y. Janjigian¹, G. O’Kane⁸, M. Onisko², J. Kaplan², A.P. Kithcart², D.E. Gutstein², A. Khorana⁹, M. F. Walsh² | ¹Memorial Sloan Kettering Cancer Center, New York, USA; ²Regeneron Pharmaceuticals, Inc. , Tarrytown, NY, USA; ³University of Ottawa, Ottawa, ON, Canada; ⁴Harvard Medical School, Boston, MA, USA; ⁵Hospital Papa Giovanni XXIII, Bergamo, Italy; ⁶Hospital Universitario 12 de Octubre, Madrid, Spain; ⁷Mayo Clinic, Rochester, MN, USA; ⁸St. Vincent's University Hospital and School of Medicine, University College Dublin, Dublin, Ireland; ⁹James P. Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, NY, USA

  ICTHIC 2026

  16-04-2026

  https://doi.org/10.4081/btvb.2026.545

  504

  PDF: 123

• PO40 | Management of paediatric patients affected by mild factor VII deficiency undergoing surgery B. Borsellino^1,2, B. Pollio¹, I. Ricca¹, R. Albiani¹, T. Martini¹ | ¹Haemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital “Città della Salute e della Scienza”, Turin; ²Department of Biomedicine and Prevention, PhD in Immunology, Molecular Medicine and Applied Biotechnology, University of Roma Tor Vergata, Roma, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.303

  564

  PDF: 12

• PO65 | Utilization of emicizumab in acquired hemophilia A: a case report C. Caputo, P. Conca, I.L. Calcaterra, E. Cimino, M. Romeo, M. Aversano, E. Franco, C. De Luca, G. D’errico, L. Jr Valletta, M. Di Minno, A. Tufano | Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.334

  618

  PDF: 26

• CO043 | LONG TERM TREATMENT WITH VITAMIN K ANTAGONIST IN PEDIATRIC PATIENTS WITH PROSTHETIC HEART VALVE: THE BERGAMO EXPERIENCE T. Zollner¹, C. Ambaglio¹, F. Duca², G. Cuni¹, E. Galimberti¹, O.C. Cretu¹, F. Schieppati¹, F. Zunino¹, V. Brusegan¹, M. Marchetti¹, A. Falanga^1|2, L. Barcella¹ | ¹Immunohematology and Transfusion Medicine, Department of Transfusion Medicine and Hematology, ERN-EuroBloodNet - European Reference Network in Rare Hematological Diseases, ASST Papa Giovanni XXIII, Bergamo, Italy; ²School of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy

  Chiara Ambaglio

  26-10-2026

  https://doi.org/10.4081/btvb.2026.745

  8

  PDF: 2

• CO059 | EXTRACELLULAR VESICLES AS BIOMARKERS IN FAMILIAL HYPERCHOLESTEROLEMIAS TREATED WITH EVINACUMAB C. Samà¹, A. Benetti¹, M.G. Lupo², M. Biolo¹, C. Portinari¹, S. Zambon¹, A. Zambon¹, N. Ferri², C.M. Radu¹, P. Simioni¹ | ¹First Chair of Internal Medicine and Thrombotic and Haemorrhagic Diseases Unit, Department of Medicine, Padova University Hospital, Padova, Italy; ²Department of Medicine, Padova University Hospital, Padova, Italy

  Chiara Sama'

  26-10-2026

  https://doi.org/10.4081/btvb.2026.761

  7

  PDF: 2

• PO30 | Acquired angioedema associated with B-non Hodgkin lymphoma: a case report A. Pozzi, G. Rosati, S. Pizzimenti, M. Padrini, S. Laurenti, G. Ferrari, R. M. Medici, C. Barale, I. Russo, A. Morotti | Univeristy of Turin, AUO San Luigi Gonzaga, Orbassano (TO), Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.291

  575

  PDF: 30

• CO-07 | ITALIAN RESOURCE USE IN MILD HEMOPHILIA A AND TYPE 1 VON WILLEBRAND DISEASE A. Gringeri^1|2, G.C. Castaman³ | ¹Fondazione Charta, Milano, Italy; ²Centro di Sanità Solidale, Lucca, Italy; ³Centre for Bleeding Disorders and Coagulation, Careggi University Hospital, Firenze, Italy

  Alessandro Gringeri

  14-10-2026

  https://doi.org/10.4081/btvb.2026.617

  69

  PDF: 14

• CO078 | METABOLOMIC AND LIPOPROTEOMIC MODULATION FOLLOWING INCLISIRAN TREATMENT IN DYSLIPIDEMIC PATIENTS J. Patrussi¹, A. Vignoli^1|2, L. Tenori^1|2, A. Sorrentino³, M. Berteotti^3|4, E. Lotti⁴, F. Crudele⁴, G. Ciarrocca Taranta³, A.A. Rogolino⁴, G. Barbieri³, A.M. Gori^3|4, R. Marcucci^3|4 | ¹Dep. of Chemistry "Ugo Schiff", University of Florence, Sesto Fiorentino, Italy; ²Magnetic Resonance Center (CERM), University of Florence, Sesto Fiorentino, Italy; ³Dep. of Experimental and Clinical Medicine, University of Florence, Firenze, Italy; ⁴Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy

  Andrea Sorrentino

  26-10-2026

  https://doi.org/10.4081/btvb.2026.780

  8

  PDF: 2

• CO-81 | DIGITAL NETWORKING FOR ACQUIRED HEMOPHILIA A: A REGION-WIDE CARE PATHWAY FROM DIAGNOSIS TO FOLLOW-UP M. Mattana¹, M.F. Mansueto², S. Raso¹, S. Siragusa^2|3, R. Tomasello¹, M. Napolitano^1|3 | ¹A.O.O.R. Villa Sofia Cervello P.O. Cervello-UOC di Ematologia per le Malattie Rare del Sangue e degli Organi Ematopoietici, Palermo, Italy; ²UOC Ematologia Policlinico P.Giaccone Palermo, Italy; ³Dipartimento Promozione della Salute, Materno-Infantile, di Medicina Interna e Specialistica di Eccellenza(PROMISE), Università degli studi di Palermo, Italy

  Marta Mattana

  14-10-2026

  https://doi.org/10.4081/btvb.2026.691

  25

  PDF: 13
• 

  The evolving landscape of gene therapy for congenital severe hemophilia: a 2024 state of the art

  Giovanni Di Minno, Gaia Spadarella, Ilenia Lorenza Calcaterra, Giancarlo Castaman, Paolo Simioni, Raimondo De Cristofaro, Cristina Santoro, Flora Peyvandi, Matteo Di Minno

  04-09-2024

  https://doi.org/10.4081/btvb.2024.144

  2083

  PDF: 359

  SUPPLEMENTARY MATERIAL: 217

• PO037 | TEMPO: A MOBILE HEALTH APPLICATION FOR PERSONALIZED MANAGEMENT OF HEMOPHILIA R. Gualtierotti^1|2, F. Franco³, L. Bedogni⁴, M. Fassi¹, A.A Giachi¹, S. Mascetti⁵, M. Manzoni⁵, F. Poggi⁶, M. Pellegrini⁶, C. Suffritti¹, F. Peyvandi^1|2 | ¹Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milano, Italy; ²Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milano, Italy; ³Department of Physics, Informatics and Mathematics (FIM), University of Modena and Reggio Emilia, Modena, Italy; ⁴Department of Sciences and Method for Engineering (DISMI), University of Modena and Reggio Emilia, Modena, Italy; ⁵Department of Computer Science, Università degli Studi di Milano, Milano, Italy; ⁶Institute for Cognitive Sciences and Technologies (ISTC), National Research Council (CNR), Bologna, Italy

  Marco Fassi

  26-10-2026

  https://doi.org/10.4081/btvb.2026.853

  7

  PDF: 2

• CO33 | Acquired hemophilia A in Liguria, Italy: what six years of data reveal C. Vernarecci¹, A. C. Molinari¹, P. Ballarino², M. Caiti², E. Cenni², P. Moscatelli², L. Banov¹ | ¹IRCCS Istituto Giannina Gaslini, Genova; ²IRCCS Policlinico San Martino, Genova, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.240

  609

  PDF: 30

• PO05 | Intensive FVIII replacement in haemophilia patients with hypertrophic synovium: a randomized study I.L. Calcaterra¹, E. Baldacci², R. Marino³, F. Valeri⁴, R.C. Santoro⁵, G. Pasta⁶, C. Martinoli⁷, M. Di Minno¹ | ¹Department of Clinical Medicine and Surgery, Federico II University, Naples; ²Haematology, University Hospital Policlinico Umberto I, Roma; ³Haemophilia Center and thrombosis, Policlinico, Bari; ⁴Regional Centre for Haemorrhagic and Thrombotic Diseases, AOU Città Della Salute e Della Scienza; Turin; ⁵Centre for Hemorrhagic and Thrombotic Disorders, Pugliese Ciaccio Hospital, Catanzaro; ⁶Fondazione IRCCS San Matteo Hospital, Pavia; ⁷Department of Health Science DISSAL, University of Genoa, Unit of Radiology and IRCCS San Martino Hospital, Genoa, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.267

  593

  PDF: 17

• PO069 | PERIOPERATIVE CHALLENGES IN ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA DURING CAPLACIZUMAB TREATMENT J. Agnelli Giacchello¹, P. Sciancalepore¹, N.F. Trincheri², L. Contino¹, M. Ladetto³, R.M. Santi¹ | ¹SSD Emostasi e trombosi e malattie rare; ²SC Laboratorio Analisi; ³SCDU Ematologia, AOU SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy

  Jacopo Agnelli Giacchello

  26-10-2026

  https://doi.org/10.4081/btvb.2026.885

  6

  PDF: 2

• CO029 | REAL WORLD EVALUATION OF A NOVEL PATIENT CENTERED OUTCOME INDICATOR TO SUPPORT VALUE BASED HEALTHCARE DECISION-MAKING IN HEMOPHILIA A IN ITALY: THE HEMPROVE NON-INTERVENTIONAL STUDY G. Castaman¹, C. Santoro², E. Ferri Grazzi³, S. Bendinelli⁴, R. Perrone⁴, C. Lainez Diaz⁴, P.A. Cortesi⁵, M.N.D. Di Minno⁶ | ¹Dep. of Oncology, Centre for Bleeding Disorders and Coagulation, Careggi Univ. Hosp., Firenze, Italy; ²Hematology, Dep. of Translational and Precision Medicine, Sapienza University of Roma, Italy; ³FedEmo, Milano, Italy; ⁴Roche S.p.A. Italy, Monza, Italy; ⁵CESP, Univ. of Milano-Bicocca, Monza, Italy; ⁶Dep. of Clinical Medicine and Surgery, Regional Reference Center for Coagulation Disorders, Federico II Univ., Napoli, Italy

  Raffaella Perrone

  26-10-2026

  https://doi.org/10.4081/btvb.2026.731

  10

  PDF: 2
• 

  PO40 | RADAR, UK-MRA MYELOMA XV - COMPARING MRD-GUIDED TREATMENT ESCALATION AND DE-ESCALATION STRATEGIES IN PATIENTS WITH NEWLY DIAGNOSED MYELOMA SUITABLE FOR STEM CELL TRANSPLANTATION: THROMBOPROPHYLAXIS SUBGROUP STUDY PROTOCOL Z. Sayar, on behalf of the RADAR Investigators | Whittington Health NHS Trust and Royal Free Hospital, London, UK

  ICTHIC 2026

  16-04-2026

  https://doi.org/10.4081/btvb.2026.534

  479

  PDF: 109

• PO097 | DETERMINANTS OF PLATELET COUNT IN A LARGE SINGLE TERTIARY CARE COHORT: IMPACT OF AGE, SEX, PLATELET REACTIVITY, CARDIOVASCULAR RISK FACTORS AND ANTIPLATELET THERAPY S. De Corci, N. Manganello, E. Schiera, S. Terracina, A. Di Battista, F.M. Pulcinelli | Experimental Medicine, Sapienza University of Rome, Italy

  Simone De Corci

  26-10-2026

  https://doi.org/10.4081/btvb.2026.913

  7

  PDF: 1

• CO102 | VARIABILITY IN ANTIPHOSPHOLIPID ANTIBODY TESTING AND TREATMENT STRATEGIES IN OBSTETRIC ANTIPHOSPHOLIPID SYNDROME: RESULTS FROM THE OAPS-CARE SURVEY, ON BEHALF OF THE EUROPEAN FORUM ON ANTIPHOSPHOLIPID ANTIBODIES A. Hoxha^1|2, E. Esteve-Valverde^3|4, G. Gobbo^1|2, F. Miró-Mur⁴, M. Radin⁵, S. De Carolis⁶, C. Trilla^7|8|9|10, A. Tincani^11|12, R. Cervera^13|14, J. Alijotas-Reig^3|15|16 | ¹Department of Medicine - DIMED, University of Padua, Padova, Italy; ²Internal Medicine Unit, Thrombosis and Bleeding Disorder, University Hospital of Padua, Padova, Italy; ³Systemic Autoimmune Diseases Unit. Department of Internal Medicine, Hospital Sant Camil, Consorci Sanitari Alt-Penedes-Garraf, Sant Pere de Ribas, Barcelona, Spain; ⁴Systemic Autoimmune Disease Research Unit. Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain; ⁵Center of Research of Immunopathology and Rare Diseases - Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, SCDU Nephrology and Dialysis, School of Specialization of Clinical Pathology, Department of Clinical and Biological Sciences, S. Giovanni Bosco Hospital, University of Turin, Torino, Italy; ⁶Fondazione Policlinico Universitario A. Gemelli IRCCS, Dipartimento di Scienze per la salute della Donna e del Bambino e di Sanità Pubblica, Roma, Italy; ⁷Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; ⁸Universitat Autònoma de Barcelona, Barcelona, Spain; ⁹Spanish Network in Maternal, Neonatal, Child and Developmental Health Research (RICORS-SAMID, RD24/0013/0001), Instituto de Salud Carlos III, 28040 Madrid, Spain; ¹⁰Women and Perinatal Health Research Group, Institut de Recerca (IR SANT PAU), Sant Quintí 77-79, 08041 Barcelona, Spain; ¹¹Rheumatology and Clinical Immunology Unit - ERN ReCONNET, ASST Spedali Civili, Brescia, Italy; ¹²Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; ¹³Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Barcelona, Catalonia, Spain; ¹⁴August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Catalonia, Spain; ¹⁵Department of Medicine. Universitat Autonoma de Barcelona, Barcelona, Spain; ¹⁶Systemic Autoimmune Disease Unit, Department of Internal Medicine, Vall d’Hebron University Hospital, Barcelona, Spain

  Ariela Hoxha

  26-10-2026

  https://doi.org/10.4081/btvb.2026.804

  8

  PDF: 2
• 

  Efficacy, safety and surgical management with concizumab prophylaxis in three young patients affected by severe hemophilia with inhibitors

  Silvia Linari, Lisa Pieri, Raffaella Pasquino, Eleonora Piellucci, Monica Attanasio, Francesca Salvianti, Giancarlo Castaman

  11-05-2026

  https://doi.org/10.4081/btvb.2026.467

  1322

  PDF: 213
• 

  Cancer-associated ischemic stroke: current knowledge and future directions

  Ronda Lun, Deborah M. Siegal

  16-05-2024

  https://doi.org/10.4081/btvb.2024.117

  3035

  PDF: 917
• 

  Anticoagulation challenges in patients with hematological malignancy-associated thrombosis and severe thrombocytopenia

  Emilie Chalayer, Géraldine Poenou, Corinne Frere

  16-04-2026

  https://doi.org/10.4081/btvb.2026.429

  380

  PDF: 170

• PO49 | Use of emicizumab in two patients with acquired hemophilia A: a new therapeutic approach S. Sorella, J. Micozzi, E. Baldacci, M. Biglietto, R. Mormile, A. Chistolini, R. Ciciani, L. Torrieri, N. Zhdanovskaya, M. Lorenzon, A. Delli Paoli, S. Ligia, C. Santoro | Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University of Roma, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.318

  658

  PDF: 25

• PO85 | Acute retinal ischemia in hemoglobin SC disease: a case report and review of the literature G. Bogoni¹, A. Bertomoro¹, E. Cosi¹, M.T. Sartori¹, R. Colombatti², G. Reggiani², M.P. Boaro², I. Bertozzi1, P. Simioni¹ | ¹Clinica Medica 1, Dipartimento di Medicina DIMED, Università degli Studi di Padova; ²Clinica di Onco-Ematologia Pediatrica, Università degli Studi di Padova, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.354

  688

  PDF: 15
• 

  Gene therapy for hemophilia B

  Pier Mannuccio Mannucci

  12-12-2025

  https://doi.org/10.4081/btvb.2025.425

  688

  PDF: 92

  HTML: 105

• PO16 | Antithrombotic treatment and outcomes in retinal vein occlusion: a retrospective cohort study and comparison with historical group S.A. Malerba^1,2, M.T. Sartori¹, G. Libralon¹, C. Dalla Porta¹, P. Simioni¹ | ¹First Medical Clinic, Department of medicine- DIMED, Università degli Studi di Padova; ²Medicina Generale, Ospedale dell’Angelo, Mestre, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.277

  607

  PDF: 11

• PO45 | Routine prophylaxis with PD-FX concentrate in severe inherited FX deficiency: a case report S. Linari, L. Pieri, M. Attanasio, F. Salvianti, M. Coppo, E. Grisanti, F. Demartis, R. Fjerza, G. Castaman | Centre for Bleeding Disorders and Coagulation, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.308

  619

  PDF: 20

• PO002 | VENOUS THROMBOEMBOLISM IN PATIENTS WITH FACTOR VII DEFICIENCY: A CASE SERIES AND REVIEW OF THE LITERATURE BM. Roccon¹, MI. Tassoni¹, G. Quintavalle¹, F. Riccardi¹, A. Matichecchia¹, GF. Rivolta¹, M. Lombardi³, R. Rossi², A. Benegiamo², A. Tagliaferri¹, A. Coppola¹ | ¹SSD Centro Hub Emofilia e Malattie Emorragiche Congenite, Azienda Ospedaliero-Universitaria di Parma, Italy; ²Lab. di Coagulazione, UOC Diagnostica Ematochimica, Azienda Ospedaliero-Universitaria di Parma, Italy; ³Centro Emostasi, UOC Medicina Interna ad indirizzo angiologico e coagulativo, Azienda Ospedaliero-Universitaria di Parma, Italy

  Antonio Coppola

  26-10-2026

  https://doi.org/10.4081/btvb.2026.818

  7

  PDF: 1
• 

  Anticoagulation during anti-angiogenic cancer therapy: balancing risks of thrombosis and bleeding

  Nikola Vladic, Florian Moik

  16-04-2026

  https://doi.org/10.4081/btvb.2026.452

  297

  PDF: 175

• PO37 | Single centre experience on anticoagulation in carriers of non-mild inherited thrombophilia: direct oral anticoagulants (DOAC) efficacy and safety M. D’uva^1,2, G. La Barba¹, G. Montanaro¹, M. Di Ianni^1,2, P. Ranalli^1,2 | ¹Hematology Unit, S. Spirito Hospital, Pescara; ²Department of Medicine and Aging Sciences, D’Annunzio University, Chieti, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.300

  644

  PDF: 21

• CO-19 | A CASE OF LOSS OF EFFICACY OF EMICIZUMAB AFTER 6 YEARS OF REGULAR USE M.R. Fasulo¹, I. Quaglia¹, A. Colombo¹, C. Lodigiani¹, M.E. Mancuso^1|2 | ¹Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy; ²Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milano, Italy

  Maria Rosaria Fasulo

  14-10-2026

  https://doi.org/10.4081/btvb.2026.629

  24

  PDF: 14

• PO70 | Clinical safety and monitoring of apixaban combined with tacrolimus and everolimus in kidney transplant patients: a prospective study S. Guglielmo¹, E. De Bon², L. Scarano¹, R. Fabris¹, E. Pierobon³, S. Barbar² | ¹Internal Medicine, Department of Medicine, Azienda ULSS 6 Euganea, Cittadella; ²Thrombotic and Hemorrhagic Disorders Unit, Department of Medicine, Azienda ULSS 6 Euganea, Cittadella; ³Nephrology and Dialysis Unit, Azienda ULSS 6 Euganea, Cittadella and Camposampiero, Padova, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.339

  632

  PDF: 25

• PO048 | EFFICACY OF RITUXIMAB TREATMENT IN A CASE OF A RELAPSED AND REFRACTORY ACQUIRED VON WILLEBRAND DISEASE SECONDARY TO PRIMARY CUTANEOUS MARGINAL ZONE B-CELL LYMPHOMA L. Gurgoglione¹, F. Saladino², E. Morsia², N. Viola³, S. Rupoli¹, A. Poloni² | ¹Clinical Hematology, AOU delle Marche, Ancona, Italy; ²Università Politecnica delle Marche, Ancona, Italy; ³Clinical Immulogy, AOU delle Marche, Ancona, Italy

  Laura Gurgoglione

  26-10-2026

  https://doi.org/10.4081/btvb.2026.864

  7

  PDF: 2

• BEST-02 | PERIOPERATIVE BLEEDING IN CHILDREN WITH LOW VON WILLEBRAND FACTOR UNDERGOING ADENOID AND TONSIL SURGERY: A 15-YEAR SINGLE-CENTER EXPERIENCE T. Martini¹, B. Borsellino^1|2, B. Pollio¹ | ¹Haemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital “Città della Salute e della Scienza”, Torino, Italy; ²Department of Biomedicine and Prevention, PhD in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Roma, Italy

  Tiziano Martini

  14-10-2026

  https://doi.org/10.4081/btvb.2026.602

  74

  PDF: 18

• PO151 | HIGH-RISK SURGERY IN SEVERE HAEMOPHILIA B: PERIOPERATIVE MANAGEMENT WITH ALBUTREPENONACOG ALFA F. Ricci, M. De Siati, M. Comand, F.G. Perretta, A. Ferretti, M. Basso, E. De Candia, R. De Cristofaro | Fondazione Policlinico Universitario Gemelli IRCCS, Roma, Italy

  Silvia Sorrentino

  26-10-2026

  https://doi.org/10.4081/btvb.2026.967

  7

  PDF: 2

• PO82 | Retrospective application of the TH2 score in a multicenter cohort of ITP patients: a reliable predictive tool or a score in need of refinement? C. Giubbilei¹, M. Defina², S. Rosati³, M. Rocco³, A. Votto⁴, F. Simonetti⁵, F. Paoletti⁶, V. Carrai¹ | ¹Hematology Unit, AOU Careggi; ²Hematology unit AOU Senese; ³Hematology Unit Azienda Sanitaria Toscana Centro; ⁴Hematology Unit, AOU Pisana; ⁵Hematology Unit, Ospedale Versilia; ⁶Hematology Unit, Azienda Sanitaria Nord Ovest, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.351

  564

  PDF: 16

• CO-71 | ACQUIRED FACTOR XIII DEFICIENCY IN A PATIENT POST-CAR-T THERAPY FOR NON-HODGKIN LYMPHOMA: A CASE REPORT A. Strangio, M. Leotta, A. Ierardi, R.C. Santoro | Hemophilia, Hemostasis and Thrombosis Unit, Azienda Ospedaliero Universitaria Renato Dulbecco, Catanzaro, Italy

  Alessandra Strangio

  14-10-2026

  https://doi.org/10.4081/btvb.2026.681

  26

  PDF: 17

• PO12 | Characterisation and real word clinical data of HEM006, a newly formulated intranasal spray desmopressin (DDAVP) to address a global treatment gap G. De Giorgi¹, A. Gringeri², R. Franceschini¹, A. Koganti³ | ¹Hemorare Srl, Italy; ²Fondazione Charta, Milan, Italy; ³Quenya LLC, USA

  22-10-2025

  https://doi.org/10.4081/btvb.2025.274

  570

  PDF: 12

• PO161 | A REGIONAL DIGITAL NETWORK FOR THE MANAGEMENT OF ACQUIRED HEMOPHILIA A: A MODEL FOR INTEGRATED CARE M. Mattana¹, S. Raso¹, R. Tomasello¹, MF. Mansueto¹, C. Cammarata², S. Siragusa³, M. Napolitano^1|3 | ¹A.O.O.R. Villa Sofia Cervello P.O. Cervello-UOC di Ematologia per le Malattie Rare del Sangue e degli Organi Ematopoietici, Italy; ²PO Sant'Elia, Caltanissetta, Italy; ³Dipartimento di Promozione della Salute, Materno-Infantile, Medicina Interna e Specialistica di Eccellenza (ProMISE), Università degli Studi di Palermo, Italy

  Marta Mattana

  26-10-2026

  https://doi.org/10.4081/btvb.2026.977

  5

  PDF: 2
• 

  PO64 | MANAGEMENT OF BLEEDING RISK IN PATIENTS WITH HEPATOCELLULAR CARCINOMA RECEIVING SYSTEMIC THERAPY: A SURVEY OF CLINICAL PRACTICE T. Van Broeckhoven^1|9, E. Van Gansewinkel^5|10, J. De Bruijne², F. Eskens³, D. De Groot⁴, K. Hermans⁵, N. Mohammad⁶, F. Van Vilsteren⁷, C. Verslype⁸, W. Moris⁹, M. Roest¹⁰, B. De Laat¹⁰ , J. De Vos-Geelen⁵, M. Kramer^1|9 | ¹Department of Gastroenterology and Hepatology, GROW – Research Institute for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, The Netherlands; ²Department of Gastroenterology & Hepatology, Utrecht University, University Medical Center Utrecht, The Netherlands; ³Department of Medical Oncology, Erasmus Medical Centre, Rotterdam, the Netherlands; ⁴Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, the Netherlands; ⁵Department of Internal Medicine, Division of Medical Oncology, GROW – Research Institute for Oncology & Reproduction, Maastricht University Medical Center, Maastricht, The Netherlands; ⁶Department of Medical Oncology, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands; ⁷Department of Gastroenterology and Hepatology, University Medical Centre Groningen, Groningen, The Netherlands; ⁸Digestive Oncology, University Hospitals Leuven, Belgium; ⁹Department of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht, The Netherlands; ¹⁰Department of Functional Coagulation, Synapse Research Institute, Maastricht, The Netherlands, on behalf of the Dutch Hepatocellular & Cholangiocarcinoma Group

  ICTHIC 2026

  16-04-2026

  https://doi.org/10.4081/btvb.2026.554

  440

  PDF: 96

• PO89 | Apixaban for secondary prevention of venous thromboembolism in hemodialysis patients: pharmacokinetic profile and safety outcomes S. Guglielmo¹, E. De Bon², L. Scarano¹, R. Fabris¹, E. Pierobon³, S. Barbar² | ¹Internal Medicine, Department of Medicine; ²Thrombotic and Hemorrhagic Disorders Unit, Department of Medicine; ³Nephrology and Dialysis Unit, Azienda ULSS 6 Euganea, Cittadella and Camposampiero, Padua, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.359

  844

  PDF: 14

• CO037 | PERFORMANCE OF A QUALITATIVE POINT-OF-CARE TEST IN PATIENTS EXPERIENCING ACUTE THROMBOEMBOLIC OR MAJOR BLEEDING EVENTS TREATED WITH DOACs: THE T-BLEEDOAC MULTICENTER PROSPECTIVE COHORT STUDY M. Vedovati¹, G. Pepe², S. Vanni³, E. Campello⁴, F. Morello⁵, S. Beccatini¹, D. Giudici¹, F. Lucarini², L. Parmeggiani³, G. Fabiani³, P. Simioni⁴, M. Santoro⁵, P. Nazerian⁶, M. Mosconi¹, C. Becattini¹ | ¹University of Perugia, Perugia, Italy; ²Versilia Hospital, Tuscany North West Health System, Lido di Camaiore (LU), Italy; ³Università di Firenze, Firenze, Italy; ⁴University of Padua, Padova, Italy; ⁵A.O.U. Città della Salute e della Scienza, Torino, Italy; ⁶Careggi University Hospital, Firenze, Italy

  Maria Cristina Vedovati

  26-10-2026

  https://doi.org/10.4081/btvb.2026.739

  6

  PDF: 1
• 

  PO13 | OUTPATIENT TREATMENT OF VENOUS THROMBOEMBOLISM AND SUBSEQUENT RISK OF CANCER S. Sørensen, D. Farkas, H. Sørensen | Department of Clinical Epidemiology, Aarhus University Hospital and Aarhus University, Aarhus, Denmark

  ICTHIC 2026

  16-04-2026

  https://doi.org/10.4081/btvb.2026.509

  434

  PDF: 102

• PO011 | A TWO CENTERS REAL-WORLD EXPERIENCE WITH ANTI-XA DIRECT ORAL ANTICOAGULANTS IN CANCER PATIENTS WITH UNUSUAL SITE VEIN THROMBOSIS U. Mazzarelli¹, L. Agrelli¹, A. Cirillo¹, C. Caputo², M. Romano², R. Russo², R. Guarrasi³, M. Triggiani¹, A. Tufano², A. Guida⁴ | ¹Dipartimento di Medicina Interna, Università degli studi di Salerno, Italy; ²Dipartimento di Medicina Interna, Università degli studi di Napoli Federico II, Italy; ³UOC Clinica Oncologica; ⁴Centro per le malattie emorragiche congenite e malattie trombotiche AOU San Giovanni di Dio e Ruggi d'Aragona Salerno, Italy

  Anna Guida

  26-10-2026

  https://doi.org/10.4081/btvb.2026.827

  6

  PDF: 2

• PO34 | A negative oncologic follow up doesn’t always really mean no cancer: two case report of cancer-associated thrombotic microangiopathy E. Cosi, A. Bertomoro, G. Bogoni, I. Bertozzi, I. Cortella, P. Simioni | Clinica Medica ORI, Azienda Ospedale-Università Padova, DIDAS, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.297

  591

  PDF: 25

• CO07 | Real word management of anticoagulant therapy in brain metastasis: moving toward a multidisciplinary approach in complex cases E. Lotti¹, C. Manneschi², S. Fancelli², F. Scolari¹, F. Crudele¹, D. Poli¹, M. Berteotti¹, D. Rossini³, S. Pillozzi², L. Antonuzzo^2,3, R. Marcucci^1,3 | ¹Disease Unit, Careggi University Hospital, Firenze; ²Oncology Unit, Careggi University Hospital, Firenze; ³Department of Experimental and Clinical Biomedical Sciences, University of Firenze, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.211

  619

  PDF: 20

• PO42 | Acquired Von Willebrad syndrome in patients with myeloproliferative syndrome: literature review and single-center experience A. Strangio, M. Leotta, A. Ierardi, R C. Santoro | UO Emofilia, Emostasi e Trombosi, AOU R Dulbecco, Catanzaro, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.305

  549

  PDF: 22

• CO18 | Relationship between gut permeability and PCSK9 in heterozygous familial hypercholesterolemia V. Castellani¹, V. Cammisotto², F. Baratta², S. Bartimoccia³, C. Nocella², L. D’erasmo¹, N. Cocomello², C. Barale⁴, R. Scicali⁵, I. Russo⁴, F. Purrello⁵, R. Carnevale³, F. Violi², M. Arca¹, P. Pignatelli² | ¹Department of Translational and Precision Medicine, Sapienza University of Roma; ²Department of Clinical, Internal Medicine, Anesthesiology and Cardiovascular Sciences, Sapienza University of Roma; ³Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Roma; ⁴Department of Clinical and Biological Sciences, University of Turin; ⁵Department of Clinical and Experimental Medicine, Internal Medicine, University of Catania, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.222

  600

  PDF: 16

• CO105 | THALIDOMIDE FOR RECURRENT GASTROINTESTINAL BLEEDING IN RARE BLEEDING DISORDERS AND VENOUS MALFORMATIONS: A MONOCENTRIC EXPERIENCE M. De Siati^1|2, F.G. Perretta^1|2, F. Ricci^1|2, A. Ferretti¹, M. Comand^1|2, S. Sorrentino¹, L. D’Innocenzo^1|2, D. Feliciani², B. Funaro², M.E. Riccioni³, A. Gasbarrini^2|4, E. De Candia^1|2 | ¹UOSD Malattie Emorragiche e Trombotiche, Fondazione Policlinico Agostino Gemelli IRCCS, Roma 00168, Italy; ²Department of Translational Medicine and Surgery, Catholic University of the Sacred Heart, Roma, Italy; ³Digestive Endoscopy Unit, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Università Cattolica del Sacro Cuore, Largo Agostino Gemelli, Roma 00168, Italy; ⁴Department of Medical and Surgical Sciences, Digestive Disease Center, Universitary Policlinic Agostino Gemelli Foundation IRCCS, Roma, Italy

  Silvia Sorrentino

  26-10-2026

  https://doi.org/10.4081/btvb.2026.807

  2

  PDF: 2

• CO-80 | EMICIZUMAB PLASMA CONCENTRATIONS AND CLINICAL OUTCOMES IN ACQUIRED HEMOPHILIA A: A REAL-WORLD SINGLE-CENTER EXPERIENCE C. Simion^1|2, E. Zanon^1|2, C. Bulato¹, B. Stocco^1|2, F. Righetto¹, F. Sartorello¹, P. Simioni^1|2 | ¹First Chair of Internal Medicine and Thrombotic and Haemorrhagic Diseases Unit, Department of Medicine, Padova University Hospital, Italy; ²Hemophilia Center, Padova University Hospital, Italy

  Chiara Simion

  14-10-2026

  https://doi.org/10.4081/btvb.2026.690

  25

  PDF: 13
• 

  Factor XI inhibitors in cancer-associated venous thromboembolism: what’s next?

  Hiranya M. Dave, Mehrie H. Patel, Keith R. McCrae, Alok A. Khorana

  16-04-2026

  https://doi.org/10.4081/btvb.2026.424

  350

  PDF: 192

• PO66 | Viscoelastic tests in disseminated intravascular coagulation associated with aortic aneurysm A. M. Pizzini¹, C. Biasoli², M. Bovara³, E. Gesuete¹, A. Fusco¹, C. Fantoni¹, P. Pedrazzi², R. Mancini³, M. Silingardi¹ | ¹Ambulatorio Emostasi & Trombosi, Dipartimento Medico, Ospedale Maggiore AUSL Bologna; ²SSI Presa in Carico delle Malattie Emorragiche e Tromboemboliche della Romagna; ³Laboratorio Unico Metropolitano AUSL Bologna, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.335

  646

  PDF: 17

• PO111 | A RARE CASE OF ACUTE PROMYELOCYTIC LEUKAEMIA PRESENTING WITH A PURELY THROMBOTIC DISSEMINATED INTRAVASCULAR COAGULATION PHENOTYPE L. Colavolpe, M. Provisione, L. Appio, S. Tupputi, N. Mumoli | ASST Valle Olona, Busto Arsizio, VA, Italy

  Lucia Colavolpe

  26-10-2026

  https://doi.org/10.4081/btvb.2026.927

  7

  PDF: 2

• PO045 | FROM PROPHYLAXIS TO ENDOGENOUS CONTROL: A SIX-MONTH REAL-WORLD EXPERIENCE WITH VALOCTOCOGENE ROXAPARVOVEC GENE THERAPY M. Basso¹, A. Ferretti¹, M. Sacco¹, S. Lancellotti¹, T. Pirozzi¹, L. Di Gennaro¹, R. De Cristofaro^1|2 | ¹Servizio Malattie Emorragiche e Trombotiche, Fondazione Policlinico Universitario Gemelli IRCCS, Italy; ²Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica S. Cuore, Roma, Italy

  Raimondo De Cristofaro

  26-10-2026

  https://doi.org/10.4081/btvb.2026.861

  6

  PDF: 2

• CO-27 | INNOVATIVE USE OF EPTACOG BETA TO TREAT ACUTE ELBOW HEMARTHROSIS IN A PEDIATRIC PATIENT WITH HEMOPHILIA B AND A HISTORY OF INHIBITORS, UNDERGOING SECONDARY PROPHYLAXIS WITH CONCIZUMAB L. Laterza¹, P. Giordano², G. Lassandro² | ¹University of Bari "Aldo Moro", Interdisciplinary Department of Medicine, Bari, Italy; ²Pediatric Haemophilia Center-AOUC Pol. Giovanni XXXIII, University of Bari “Aldo Moro”, Bari, Italy

  Luisa Laterza

  14-10-2026

  https://doi.org/10.4081/btvb.2026.637

  29

  PDF: 15

• CO06 | Recurrences of catheter associated upper extremity deep vein thrombosis in cancer: a two year prospective study with enoxaparin M. Sartori, A. Trentini, S. Cavara, L. Borgese, M. Soldati, B. Cosmi | Angiology and Blood Coagulation Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.210

  674

  PDF: 27

• CO-35 | TRANSITION FROM A PAEDIATRIC REFERRAL CENTER TO AN ADULT CENTER IN INHERITED BLEEDING DISORDERS: A REAL-WORLD COHORT STUDY I. Ricca¹, A. Casson¹, T. Martini², B. Borsellino², A. Barchieri¹, G. Guido¹, P. Ocello¹, M. Tucciarone¹, R. Albiani², B. Pollio², G. Delios¹ | ¹Centro Malattie Trombotiche ed Emorragiche - SC Servizio Trasfusionale ASL TO4, Ivrea, Italy; ²Centro Esperto Malattie Emorragiche Congenite in Età Pediatrica e della Donna in Gravidanza - SSD Medicina Trasfusionale Materno-Infantile e Traumatologica, Città della Salute e della Scienza di Torino, Italy

  Irene Ricca

  14-10-2026

  https://doi.org/10.4081/btvb.2026.645

  24

  PDF: 9

• PO19 | Joint health status in patients with moderate hemophilia A: a cross-sectional multi-center study I.L. Calcaterra¹, F. Picasso², F. Valeri³, E. Baldacci⁴, M. Napolitano⁵, C. Guerrino¹, E. Zanon⁶, C. Santoro⁴, S. Siragusa⁷, C. Martinoli², M. Di Minno¹ | ¹Department of Clinical Medicine and Surgery, Regional Reference Centre for Coagulation Disorders, Federico II University, Naples; ²Department of Health Sciences “DISSAL”, Università di Genova; ³Regional Centre for Hemorrhagic and Thrombotic Diseases, AOU Città della Salute e della Scienza, Turin; ⁴Haematology, Department of Translational and Precision Medicine, Sapienza University, Roma; ⁵Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo and Haematology Unit and Rare Disorders Hospital “V. Cervello”, Palermo; ⁶Haemophilia Centre, General Medicine, Padua University Hospital, Padua; ⁷Department PROMISE, University of Palermo, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.279

  594

  PDF: 24
• 

  Crosstalk between hemostasis inhibitors and cholesterol biomarkers in multiple sclerosis

  Robert Parambi, Nicole Ziliotto, Francesco Bernardi , Marcello Baroni , Richard W Browne , Dejan Jakimovski, Bianca Weinstock-Guttman, Robert Zivadinov, Murali Ramanathan

  17-10-2022

  https://doi.org/10.4081/btvb.2022.41

  2853

  PDF: 491

  Supplementary Files: 144

• PO044 | UPDATING MANAGEMENT OF ACQUIRED HEMOPHILIA A USING EMICIZUMAB: REAL-WORLD OUTCOMES BY A COLLABORATIVE NETWORK OF 3 ITALIAN CENTERS MI. Tassoni¹, BM. Roccon¹, A. Dalla Salda², R. Benedetti³, R. Rossi⁴, C. Cattabiani⁴, G. Quintavalle¹, A. Casali², D. Imberti³, A. Coppola¹ | ¹SSD Centro Hub Emofilia e Malattie Emorragiche Congenite, Azienda Ospedaliero-Universitaria di Parma, Italy; ²SOC Medicina Interna per acuti ad indirizzo metabolico ed emocoagulativo, Azienda USL IRCCS Reggio Emilia, Italy; ³Centro Emostasi e Trombosi, Medicina Interna, Azienda USL Piacenza, Italy; ⁴Lab. di Coagulazione, UOC Diagnostica Ematochimica, Azienda Ospedaliero-Universitaria di Parma, Italy

  Antonio Coppola

  26-10-2026

  https://doi.org/10.4081/btvb.2026.860

  6

  PDF: 2

• CO41 | Failure in assisted reproductive techniques: insights from the first registry E. Grandone^1,3,4, C. Lodigiani², D. Colaizzo³, M. Passaretti², J. Khizroeva⁴, A. De Laurenzo³, P. Totaro⁵, E. Bucherini⁶, D. Baldini⁷, V. Bitsadze⁴, A. Makatsarya⁴, M. Mastroianno³, G. Piazza⁸, M. Othman⁹, M. Margaglione¹ | ¹University of Foggia, Italy; ²Humanitas University, Rozzano, Italy; ³IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy; ⁴First Sechenov University, Russia; ⁵Santa Maria Hospital, Bari, Italy; ⁶Angiologia, Faenza, Italy; ⁷Momo Fertilife, Bisceglie, Italy; ⁸Brigham Women Hospital, USA; ⁹Queen’s University, Kingston, Canada

  22-10-2025

  https://doi.org/10.4081/btvb.2025.310

  572

  PDF: 14

• CO32 | Major surgery in patients with severe hemophilia A without inhibitors receiving prophylaxis with fitusiran E. Zanon, C. Simion, A. Napolitano, L. Spiezia, P. Simioni | Haemophilia Center, First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.239

  558

  PDF: 24
• 

  Factor XI inhibitors: a new option for the prevention and treatment of cancer-associated thrombosis

  Marcello Di Nisio, Matteo Candeloro, Nicola Potere, Ettore Porreca, Jeffrey I. Weitz

  16-05-2024

  https://doi.org/10.4081/btvb.2024.118

  1900

  PDF: 1304
• 

  Bleeding in cancer: epidemiological aspects

  Kelsey Bria, Amir Mahmoud, Kristen M. Sanfilippo

  16-04-2026

  https://doi.org/10.4081/btvb.2026.453

  890

  PDF: 176
• 

  New perspectives for prevention of the post-thrombotic syndrome

  Paolo Prandoni

  22-03-2022

  https://doi.org/10.4081/btvb.2022.20

  2279

  PDF: 659

• CO006 | PREVALENCE OF GASTROINTESTINAL BLEEDING IN GLANZMANN THROMBASTHENIA PATIENTS: RESULTS OF A WORLDWIDE SURVEY E. Falcinelli¹, L. Bury¹, S. Morais², M. de Oliveira², M. Kannan³, M. Faranoush⁴, D. Desprez⁵, V. Jean-Baptiste⁶, C. Santoro⁷, C. Falaise⁸, P. Saultier⁸, M. Fiore⁹, C. Albayrak¹⁰, A. Sánchez¹¹, J.M. Bastida¹², A. Artoni¹³, G. Castaman¹⁴, K. Gomez¹⁵, R. Schutgens¹⁶, L. Spiezia¹⁷, M. Sridharan¹⁸, N. Butta¹⁹, P. Buur van Kooten Niekerk²⁰, E. Leinøe²¹, B. Guillet²², C. Panagiotis²³, S. Crivelli²⁴, E. De Candia²⁵, M. Lewandowska²⁶, P. De Bonis²⁷, G. Kenet²⁸, F. Heubel-Moenen²⁹, J. Payne³⁰, L. Banov³¹, L. Puccetti³², M. Olivieri³³, M. Chitlur³⁴, M. Lambert³⁵, A. Pecci³⁶, D. Martínez-Carballeira³⁷, E. Zetterberg³⁸, J. Curnow³⁹, M. Napolitano⁴⁰, A. Morotti⁴¹, R.C. Santoro⁴², R. Johann⁴³, S. Saulyte Trakymiene⁴⁴, A. Falanga⁴⁵, C. Casas⁴⁶, E. Zanon⁴⁷, J. Moppet⁴⁸, N.M. Popa-Fotea⁴⁹, P. Gresele¹ | ¹Department of Medicine and Surgery, Section of Internal and Cardiovascular Medicine, University of Perugia, Italy; ²Centro Hospitalar Universitário de Santo António, Portugal; ³Blood and Vascular Biology Research Lab, Department of Biotechnology, Central University of Tamil Nadu, India; ⁴Iranian Hemophilia and Thrombophilia Association, MAHTA, Iran; ⁵CRC MHC Hopital Universaitire de Strasbourg, France; ⁶CHRU de Tours, University Hospital of Tours, France; ⁷UOC Ematologia, Azienda Ospedaliero Universitaria Policlinico Umberto I, Roma, Italy; ⁸AP-HM Timone, Marseille, France; ⁹CHU Bordeaux, France; ¹⁰Mayıs University Medical Faculty Pediatric Hematology and Oncology Dept, Türkiye; ¹¹Hospital Universitario Morales Meseguer – Centro Regional de Hemodonación, Murcia, Spain; ¹²Complejo Asistencial Universitario De Salamanca, Spain; ¹³Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy; ¹⁴Azienda Ospedaliera Universitaria Careggi Florence, Italy; ¹⁵Royal Free Hospital, London, UK; ¹⁶Center for Benign Haematology, Thrombosis and Haemostasis, Van Creveldkliniek, UMC Utrecht, The Netherlands; ¹⁷University of Padova, Italy; ¹⁸Mayo Clinic, Rochester, USA; ¹⁹Hospital Universitario La Paz-IdiPAZ, Madrid, Spain; ²⁰Aarhus University Hospital, Denmark; ²¹Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; ²²University Hospital of Rennes, France; ²³Blood unit and National Reference Center for Congenital Bleeding Disorders, ''Laiko'' General Hospital, Greece; ²⁴Ospedale L. Sacco e Polo Universitario, Milano, Italy; ²⁵Università Cattolica del Sacro Cuore-Roma, Fondazione Policlinico Universitario A. Gemelli IRCCS, Italy; ²⁶Indiana Hemophilia and Thrombosis Center Innovative Hematology, USA; ²⁷IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy; ²⁸Sheba Medical Center, Israel; ²⁹Department of Hematology Internal Medicine, Maastricht University Medical Center and Hemophilia Treatment Center Nijmegen Eindhoven Maastricht and CARIM, Maastricht University, Maastricht, Netherlands; ³⁰Sheffield Children’s NHS foundation Trust, UK; ³¹Hemostasis and Thrombosis Unit, Gaslini Children’s Hospital, Italy; ³²University Teaching Hospital of Siena, Italy; ³³Pediatric Thrombosis and Hemostasis Unit, Dr. von Hauner Childreńs Hospital, LMU Munich, Munich, Germany; ³⁴Children's Hospital of Michigan, USA; ³⁵Children’s Hospital of Philadelphia, USA; ³⁶IRCCS Policlinico San Matteo Foundation and University of Pavia, Italy; ³⁷Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Spain; ³⁸Department of Hematology, Coagulation Unit, Skane University hospital, Sweden; ³⁹Westmead Hospital, Sydney, Australia; ⁴⁰PROMISE Department, University of Palermo, Italy; ⁴¹AOU San Luigi Gonzaga Hospital, University of Turin, Italy; ⁴²Hemostasis and Thrombosis, Az. Osp. Univ. Dulbecco, Catanzaro, Italy; ⁴³Hospital Center of Le Mans, France; ⁴⁴Vilnius University Hospital Santaros Klinikos, Lithuania; ⁴⁵ASST Papa Giovanni XXIII, Bergamo, Italy; ⁴⁶Hospital San José, Bogotà, Colombia; ⁴⁷Haemophilia Center-General Medicine, Padova University Hospital, Padova, Italy; ⁴⁸University Hospitals Bristol NHS Foundation Trust, UK; ⁴⁹University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania

  Loredana Bury

  26-10-2026

  https://doi.org/10.4081/btvb.2026.708

  7

  PDF: 2

• CO-78 | REAL-WORLD MANAGEMENT OF ACQUIRED HEMOPHILIA A: FOCUS ON RECOMBINANT PORCINE FVIII AS FIRST-LINE HEMOSTATIC TREATMENT AND LONG-TERM OUTCOMES M. Leotta, A. Strangio, A. Ierardi, R.C. Santoro | Hemophilia, Hemostasis and Thrombosis Centre, Azienda Ospedaliero Universitaria Renato Dulbecco, Catanzaro, Italy

  Marzia Leotta

  14-10-2026

  https://doi.org/10.4081/btvb.2026.688

  22

  PDF: 15
• 

  Anticoagulant treatment in patients with internal jugular vein thrombosis: a case serie

  Arianna Pannunzio, Ilaria Maria Palumbo, Luca Tretola, Elena Ciambella, Valentina Castellani, Maddalena Ragazzo, Pasquale Pignatelli, Emanuele Valeriani

  14-10-2026

  https://doi.org/10.4081/btvb.2026.422

  273

  PDF: 40

• CO-22 | CLINICAL FEATURES IN PATIENTS WITH NON-SEVERE HEMOPHILIA A: THE DISCOVERY SCORE PROPOSAL FOR PROPHYLAXIS PRESCRIPTION M.N.D. Di Minno¹, E. Baldacci², C. Biasoli³, A. Borchiellini⁴, F. Daniele⁵, P. Di Gregorio⁶, C. Gorio⁷, G. Malcangi⁸, E. Marchesini⁹, I. Ricca¹⁰, R. Santoro¹¹, S. Siragusa¹², M.R. Villa¹³, E. Zanon¹⁴, A. Tagliaferri¹⁵, A. Coppola¹⁵ | ¹Hub Centre for Thrombotic and Hemorrhagic Disorders, Federico II University Hospital, Napoli, Italy; ²Haematology, University Hospital Policlinico Umberto I, Roma, Italy; ³Interdepartmental Simple Structure for the Management of Hemorrhagic and Thromboembolic Diseases, M. Bufalini Hospital, Cesena, Italy; ⁴Regional Centre for Hemorrhagic and Thrombotic Diseases, AOU Città della Salute e della Scienza, Torino, Italy; ⁵Haemostasis and Thrombosis Service, Ospedale Civile dell'Annunziata, Cosenza, Italy; ⁶Transfusion Medicine Department, "SS. Annunziata" Hospital, Chieti, Italy; ⁷Pediatric Onco-Hematology Unit, Children's Hospital, ASST-Spedali Civili, Brescia, Italy; ⁸Haemophilia and Thrombosis Center, University Hospital Policlinico-Giovanni XXIII, Bari, Italy; ⁹Hemophilia Centre, SC Vascular and Emergency Department, University of Perugia, Italy; ¹⁰Centro Emofilia, Città della Salute e della Scienza, Torino, Italy; ¹¹Hemostasis and Thrombosis Unit, Azienda Ospedaliero Universitaria Dulbecco, Catanzaro, Italy; ¹²Centro di Riferimento Regionale per le Emocoagulopatie Congenite, Palermo, Italy; ¹³Hematology Unit, Ospedale Santa Maria di Loreto, Napoli, Italy; ¹⁴Hemophilia and Thrombosis Center, University Hospital of Padua, Italy; ¹⁵Hemophilia and Thrombosis Center, Azienda Ospedaliera di Parma, Italy

  Matteo Di Minno

  14-10-2026

  https://doi.org/10.4081/btvb.2026.632

  33

  PDF: 11